Position in MYGN
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$276,660
+$91,564 QoQ
Shares Held
61,480
+104.3% QoQ
Ownership
0.065%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2023
6 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in MYGN Over Time
Shares Held
Position Value (USD)
Position in Diagnostics & Research
Healthcare · as of Mar 31, 2026Graham Capital Management, L.P. holds $24,157,603 across 16 Diagnostics & Research names. MYGN ranks #10 (1.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | IQV |
Iqvia Holdings Inc.
|
45,475 | $7,755,306 | |
| 2 | NTRA |
Natera, Inc.
|
25,746 | $5,148,942 | |
| 3 | A |
Agilent Technologies, Inc.
|
42,055 | $4,793,428 | |
| 4 | DHR |
Danaher Corp /De/
|
13,572 | $2,573,251 | |
| 5 | IDXX |
Idexx Laboratories Inc /De
|
1,171 | $657,973 | |
| 6 | MEDP |
Medpace Holdings, Inc.
|
1,178 | $565,663 | |
| 7 | VCYT |
Veracyte, Inc.
|
14,180 | $456,737 | |
| 8 | TMO |
Thermo Fisher Scientific Inc.
|
891 | $437,953 |
All Filings in MYGN
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $276,660 | 61,480 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $185,096 | 30,097 | Shares | Sole | 2026-02-17 | |
| 2025-03-31 | $632,865 | 71,349 | Shares | Sole | 2025-05-15 | |
| 2024-09-30 | $1,183,330 | 43,203 | Shares | Sole | 2024-11-14 | |
| 2024-06-30 | $399,994 | 16,353 | Shares | Sole | 2024-08-14 | |
| 2023-06-30 | $204,331 | 8,815 | Shares | Sole | 2023-08-14 | |
| No filing history on record for this holder in this stock. | ||||||